New Horizons in Dyslipidemia Management in Primary Care
Type: Accredited Symposia
Thursday May 10 6:00pm to 7:00pm Location: Symposia C
Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently competed clinical trials.
Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardiovascular disease.
Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies.
Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics.
This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Ontario Chapter.
This program was supported in part by an educational grant from Amgen.
Ronald Goldenberg MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital
& LMC Diabetes & Endocrinology,
Dr. Ronald Goldenberg is a consultant endocrinologist affiliated with North York General Hospital (NYGH) in Toronto, Ontario, and LMC Diabetes & Endocrinology in Thornhill. He completed his residency in Internal Medicine in 1987 at the University of Toronto, and his fellowship in Endocrinology & Metabolism in 1989 at the University of Toronto. His major areas of interest include clinical care of diabetes, obesity, dyslipidemia and thyroid disorders.
Dr. Goldenberg has been an investigator in a wide array of clinical trials in the areas of diabetes, hypertension, obesity, and dyslipidemia. He has been actively involved in continuing medical education for the last three decades, with a strong focus on translating evidence-based medicine into practical patient care. As a key opinion leader among endocrinologists in Canada, Dr. Goldenberg continues to strive for improved patient outcomes by providing ongoing education to patients, physicians, nurses, dietitians and pharmacists, both nationally and internationally. He has been awarded an Honorable Citation by the Medical Staff Association of NYGH for excellence in the practice of endocrinology and dedication to patient care in the community.
Dr. Goldenberg was a councillor on the Canadian Diabetes Association (CDA; now Diabetes Canada) Clinical & Scientific Section Executive Committee from 2010 to 2016. He was a member of the Steering Committee and an author for the 2013 CDA Clinical Practice Guidelines (CPGs), lead author of the CDA March 2016 Interim Update and co-author of the November 2016 Interim Update on the Pharmacologic Management of Type 2 Diabetes. He is on the Executive Committee and an author for the 2018 Diabetes Canada CPGs. Dr. Goldenberg is also the head of eCHE for the Canadian Society of Endocrinology & Metabolism (CSEM), and a member of the Executive Board of the Canadian Society for the Study of the Aging Male.
Dr. Goldenberg is a past Medical Director of the Diabetes Education Centre at NYGH and North York Branson Hospital. He is a past-Chair of the Ontario Medical Association Section on Endocrinology & Metabolism, and a previous President of the Toronto Diabetes Association.
Dr. Goldenberg is a longstanding member of Diabetes Canada, American Diabetes Association, Endocrine Society, American Association of Endocrinologists, European Association for the Study of Diabetes, CSEM, and a Fellow of the American College of Endocrinology.